# Holistic Management of Multiple Myeloma: A Case Report on Siddha Therapy as an Adjunct to the Bortezomib-Lenalidomide-Dexamethasone (BLD) Regimen

## TL;DR

This case report explores using Siddha therapy alongside standard chemotherapy to treat multiple myeloma, showing improved patient outcomes.

## Contribution

The paper presents a novel integration of Siddha medicine with conventional BLD therapy for multiple myeloma management.

## Key findings

- The patient showed significant improvements in haematological parameters after six months of treatment.
- Siddha therapy helped alleviate symptoms like weakness and insomnia alongside conventional chemotherapy.
- Quality of life and general physical condition improved with the combined treatment approach.

## Abstract

Multiple myeloma (MM) is a complex haematological malignancy characterized by the clonal proliferation of plasma cells within the bone marrow. It is the second most common haematological malignancy that presents in elderly patients. The integration of complementary medicine into conventional cancer care is increasingly observed among patients, driven by factors such as symptom management, holistic well-being, and cultural alignment. This case report presents the integrated management of a 65-year-old male patient diagnosed with MM, who received both chemotherapy and Siddha medicine to alleviate constitutional symptoms and improve overall well-being. The patient complained of weakness, easy fatigability, and insomnia. The diagnosis of MM was established elsewhere through serum protein electrophoresis, immunofixation, and bone marrow biopsy. He was treated with the bortezomib, lenalidomide, and dexamethasone (BLD) regimen along with a combination of Siddha herbal and herbo-mineral formulations. After six months, the patient demonstrated significant improvements in haematological parameters, general physical condition, and quality of life. This case highlights the potential benefits of integrating traditional Siddha medicine with conventional allopathic therapy in managing MM.